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A 52-year-old male patient was treated with standard radiochemotherapy with temo-
zolomide for glioblastoma multiforme (GBM). After worsening of his clinical condition, 
further tumor-specific treatment was unlikely to be successful, and the patient seeked 
help from an alternative practitioner, who administered a combination of dichloroacetate 
(DCA) and artesunate (ART). A few days later, the patient showed clinical and laboratory 
signs of liver damage and bone marrow toxicity (leukopenia, thrombocytopenia). Despite 
successful restoration of laboratory parameters upon symptomatic treatment, the patient 
died 10 days after the infusion. DCA bears a well-documented hepatotoxic risk, while 
ART can be considered as safe concerning hepatotoxicity. Bone marrow toxicity can 
appear upon ART application as reduced reticulocyte counts and disturbed erythropoi-
esis. It can be assumed that the simultaneous use of both drugs caused liver injury and 
bone marrow toxicity. The compassionate use of DCA/ART combination therapy outside 
of clinical trials cannot be recommended for GBM treatment.
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INtRoDUCtIoN
Glioblastoma multiforme (GBM) is an aggressive brain tumor that is currently treated with a com-
bination of radiotherapy and temozolomide (TMZ) chemotherapy. The prognosis is unfavorable 
with an average survival of 15 months (1–3). In this desperate situation, it is not uncommon for 
patients to seek help outside standard medicine from alternative practitioners and healers. Often, 
non-approved remedies or unproven combination of drugs are prescribed, which occasionally may 
lead to undesired side effects or even life-threatening toxicities.
Dichloroacetate (DCA) is generated as by-product of chlorination of drinking water and by 
metabolitzation of drugs and chemicals (4). DCA accumulation in groundwater is considered as 
Abbreviations: ARS, artemisinin; ART, artesunate; DCA, dichloroacetate; GBM, glioblastoma multiforme; TMZ, temozolo-
mide; VA, valproic acid.
FIGURe 1 | time course of leukocyte (a), thrombocyte (B) count, serum levels of aLat (C), asat (D), g-Gt (e), and CRp (F). Radiotherapy with 
Temozolomide as indicated between 53 and 92 days after surgery. Infusion with ART and DCA is labeled 148 days after surgery.
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potential health hazard. In vitro and in vivo investigations showed 
that DCA inhibits tumor growth by redirecting glycolysis to 
oxidative phosphorylation and oxidative removal of lactate via 
pyruvate (5). Although five GBM patients have been previously 
treated with DCA (6), there is only limited knowledge about the 
efficacy or toxicity of DCA in cancer therapy.
In addition to their antimalarial activity, the artemisinin 
(ARS) derivatives [artesunate (ART), artemether, dehydroarte-
misinin] also exert anticancer activity in vitro and in vivo (7–13), 
including some brain tumor models (14–18). Compassionate use 
of ARS-type drugs encouraged the initiation of phase I/II trials 
in cancer patients (19–27). Most of these studies report are case 
reports or consist of only small numbers of patients. Therefore, 
there is still limited evidence regarding the safe use of ARS in 
cancer patients.
In the present case report, we describe a patient, who died with 
severe liver and bone marrow toxicity after intake of combined 
DCA and ART.
Case RepoRt
A 52-year-old male patient was diagnosed with GBM after 
suffering for several weeks from cognitive decline, headaches, 
gait ataxia, and a series of epileptic seizures. The initiation of 
adjuvant therapy was delayed by complicated wound healing, 
but finally – 53 days after surgery – radiotherapy up to 60 Gy of 
the tumor region was initiated with simultaneous TMZ chemo-
therapy (75 mg/m2) according to local guidelines (28).
The general state of health was unfavorable (Karnofsky 
score: 50). The patient suffered from right-side hemiparesis and 
taBLe 1 | Causality assessment of adverse reactions to the DCa/aRt combination treatment according to RUCaM (29, 30).
Criterion observation Given score score range
1. Time to onset of the reaction Toxic reaction 6 days after treatment 2 (+1 to +2)
2. Course of the reaction Decrease <50% within 30 days 3 (−2 to +3)
3. Risk factors for drug reaction Age of patient ≥55 years 0 (0 to +1)
4. Concomitant drugs No information 0 (−3 to 0)
5. Non-drug-related causes HAV, HBV, and HCV serology missing, no biliary obstruction, no alcoholism, no hypotension 0 (−3 to +2)
6. Previous information on the drug Hepatotoxicity published, but unlabeled 1 (0 to +2)
7. Response to readministration Not possible, because patient died 0 (−2 to +3)
Total 6
Quantitative grading of causality: ≤0, excluded; 1–2, unlikely; 3–5, possible; 6–8 probable; ≥9, highly probable.
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required considerable help and medical assistance. Therefore, 
adjuvant TMZ chemotherapy was ruled out, and rehabilitation 
actions were initiated. Rehabilitation had to be discontinued 
128  days after surgery, because of another series of epileptic 
seizures. Antiepileptic treatment was escalated to 1800 mg valp-
roic acid (VA), 3000 mg levetiracetam, 200 mg lacosamide, and 
20 mg clobazam. Progressive intracranial tumor burden by CT 
and Fet-PET scan diagnosis was considered as non-suitable for 
tumor-specific treatment, and steroid medication was escalated.
At that point, the patient and his family were seeking help 
from an alternative practitioner. An unknown amount of DCA 
was administered and ART (2.5 mg/kg bodyweight) was intrave-
nously infused 148 days after surgery. At that time, the patient had 
a stable/unchanged concomitant medication. The patient’s cogni-
tive condition declined during the following days with adynamia, 
severe headaches, and psychomotoric retardation in rapid change 
with signs of delusions. After admission to the hospital, epileptic 
activity was not found by EEG and CT scanning did not show rel-
evant changes concerning mass effect or edema. However, blood 
examinations showed signs of exsiccosis, pancytopenia, and 
markedly increased hepatic enzyme activities (Figure 1). Upon 
fluid substitution, laboratory parameter stabilized. However, 
two days after hospitalization, the state of the patient suddenly 
deteriorated with hypotension, systemic signs of infection, and 
a series of epileptic seizures. Discussing the need for intensified 
medical intervention and possible mechanical ventilation, the 
family did not wish these the actions to be undertaken according 
to the patient’s provision. The patient died during the course of 
the following night and 157 days after surgery.
The timing of events can be summarized as follows:
• Surgery at day 0
• Start of radiotherapy 53 days after surgery
• End of radiotherapy 92 days after surgery
• Infusion of ART and DCA 148 days after surgery
• First signs of toxicity 154  days after surgery (elevated liver 
enzymes and hematotoxicity)
• Death of the patient 157 days after surgery
A valuable measure for the causality of adverse reactions of 
drugs in patients with liver injury is the Roussel Uclaf Causality 
Assessment Method (RUCAM) (29, 30). RUCAM considers all 
relevant criteria for liver injury by drugs. We applied the RUCAM 
scoring system to the patient presented here and found an overall 
quantitative grading of causality of 6, which indicates reasonable 
probability that the combinational administration of DCA and 
ART caused liver injury (Table 1).
DIsCUssIoN
The severity and outcome of this case of compassionate use of 
alternative medication is remarkable. While the hepatotoxic 
potential of DCA is well documented, ART is actually consid-
ered a rather safe antimalarial drug. It can be speculated that the 
specific combination of both drugs provoked fatal liver and bone 
marrow toxicity in the patient.
At the day of hospitalization, prior alternative medication had 
not been declared by the patient. Therefore, liver toxicity by VA or 
TMZ has been suspected. In the past, severe and even fatal toxic-
ity were reported for both for VA (31–36) and for TMZ (37–40). 
Taking into account the additional sudden decline in leukocyte 
and thrombocyte counts during the next days and considering 
the prior normal values made this possibility, however, rather 
unlikely. The dynamics of TMZ- or VA-caused liver damage usu-
ally represent more continuous processes. The nadir of TMZ is 
expected after 21 days. Even delayed forms of bone marrow toxic-
ity are not comparable to the dramatic decline observed here.
The cause of death remains speculative, since an autopsy was 
not performed in accordance to the patient’s provision and fam-
ily wishes. We consider aspiration pneumonia or spontaneous 
internal bleeding as possible causes for the sudden decline of 
blood pressure.
As shown in Table 2, DCA administration in animal experi-
ments induced hepatotoxicity and hepatocarcinogenesis. DCA 
increased hepatic oxidative stress and disturbed liver metabolism. 
Although treatment of five GBM patients with DCA did not 
reveal hepatotoxicity (6), there is evidence from preclinical in vivo 
experiments that DCA affects the liver (Table 2) (4, 41). However, 
a straightforward conclusion to the observed hepatotoxicity in 
the present case is difficult, because the dose of applied DCA to 
the patient was not disclosed by the alternative practitioner.
The clinical safety of ART is well documented. Large clinical 
trials and meta-analyses of clinical trials dealing with many thou-
sands of malaria patients did not unravel serious adverse effects 
(59, 60). Preclinical toxicity studies gave some hints for neurotox-
icity, embryotoxicity, genotoxicity, hematotoxicity, cardiotoxicity, 
nephrotoxicity, and allergic reaction (61). Long-term application 
of low ARS concentrations may be more toxic than short-term 
application of high doses. This may explain, why toxicities can 
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be observed in animal experiments, but not in human studies. 
A large meta-analysis with 5000 malaria patients revealed that 
hepatotoxicity was a rare event, and elevated liver enzymes have 
been found in 0.9% of all cases (59). Although most papers on 
clinical safety were published in the context of malaria treatment, 
there are also some reports on the use of ARS-derivatives in 
cancer patients. Case reports on the compassionate use of ART 
or artemether in patients, with laryngeal squamous cell carci-
noma, uveal melanoma, pituitary macroadenoma, and prostate 
carcinoma, reported that the ARSs were well tolerated with no 
additional side effects in addition to those caused by standard 
chemotherapy. A randomized controlled trial with 120 advanced 
non-small cell lung cancer patients on vinorelbine alone versus 
vinorelbine plus ART did not find significant differences in toxic-
ity between the two treatment groups (23). In a pilot phase I/II 
trial in 10 patients suffering from cervical carcinoma, artenimol 
reduced clinical symptoms, vaginal discharge, and pain, and no 
adverse events of grade 3 and 4 were observed (24). Another 
phase I/II pilot study in veterinary cancers was conducted in 
23 dogs with non-resectable tumors. No neurological or cardiac 
toxicity was observed, and seven dogs exhibited no adverse effects 
taBLe 2 | Literature survey on hepatotoxicity by DCa in vivo.
experimental 
model
treatment dose Route of  
administration
Duration of  
treatment
effect Reference
Dogs 300 mg/kg Intravenously 1 h Decrease of tissue lactate levels in liver (42)
B6C3F1 mice 1–2 g/L Drinking water 52 weeks Enlarged livers, cytomegaly, and glycogen accumulation (43)
B6C3F1 and  
Swiss-Webster mice
300–2000 mg/L Drinking water 14 days Tumorigenesis is influenced by necrosis and reparative hyperplasia, 
increased 3H-thymidine labeling index
(44)
B6C3F1 mice 200–600 mg/L Drinking water 72 h Markedly enlarged liver, cytomegaly, glycogen accumulation, 
recurrent liver necrosis with high proliferation rates, peroxisome 
induction, and lipofuscin accumulation
(45)
B6C3F1 mice 2.0 g/L Drinking water 38 or 
50 weeks
Induction of hepatocellular lesions with increased cell divisions; 
increased c-Jun/c-Fos expression
(46)
B6C3F1 mice 0.5 g/L Drinking water 2 weeks 4-fold increase of in vitro colony formation of hepatocytes 
suggesting promotion of clonal expansion of anchorage-
independent hepatocytes in vivo
(47)
B6C3F1 mice 2 g/L Drinking water 48 weeks Increase of tumor growth rates (48)
B6C3F1 mice 0.2–3 g/L Drinking water 4–12 weeks Increase of glycogen concentration in liver (49)
B6C3F1 mice 0.1–2 g/L Drinking water 2–10 weeks Reduction of serum insulin, downregulation of insulin receptor, and 
increased MAP kinase phosphorylation
(50)
B6C3F1 mice 0.5 or 2 g/L Drinking water 35–52 weeks Induction of liver tumors, which were c-Jun-positive (51)
Fischer-344 rats 0.05–20 mg/kg Intravenously  
or by gavage
7 days Oral bioavailability was 0–13% in control rats and 14–75%  
in GSTZ-depleted rats
(52)
Sprague-Dawley rats 2.5 μg–50 mg/kg/day Drinking water 12 weeks GSTZ1-1 activity and expression decreased to 95–100% and 
recovered 8 weeks after cessation
(53)
B6C3F1 mice 300 mg/kg By gavage 6 or 12 h Increased production of superoxide anion, lipid peroxidation, and 
DNA-single strand breaks
(54)
B6C3F1 male mice 7.7–410 mg/kg/day By gavage 4 or 13 weeks Hepatomegaly at 410 mg/kg/day. Dose-dependent increase of SOD 
activity, lipid peroxidation, and DNA-single strand breaks
(55)
Sprague-Dawley rats 500 mg/kg/day By gavage 8 weeks Dechlorination of DCA was higher in cytosol than in mitochondria 
by GSTZ1
(56)
PKD rats 75 mg/L Drinking water 8 weeks Only male rats with polycystic kidney disease (PKD) showed 
increased disease severity (cystic enlargement and proteinuria)
(57)
B6C3F1 mice 7.5–30 mg/kg/day By gavage 13 weeks Dose-dependent increase of SOD production, lipid peroxidation and 
DNA-single strand breaks
(58)
at all. Fever and hematological or gastrointestinal toxicity, mostly 
transient, occurred in 16 dogs. One dog died from treatment-
unrelated pneumonia (25). As reported from a randomized, 
double-blind placebo-controlled pilot study in 23 colorectal 
cancer patients, oral ART therapy was well tolerated without 
signs of hepatotoxicity (26). Another recent phase I trial on 
23 metastasized breast cancer patients reported that four patients 
had adverse events of the auditory system possibly related to the 
intake of ART. However, none of these side effects were severe 
adverse events. Four patients had adverse events concerning the 
vestibular system, one of which was severe, but fully reversible 
after discontinuation of ART treatment (27). In summary, hepa-
totoxicity has not been found in any of these patients.
Hematotoxicity is worth mentioning in this context, because 
the patient suffered from reduced leukocyte and thrombocyte 
counts. The toxicity of ARS-type drugs on leukopoiesis is contro-
versially discussed, and both enhanced and inhibited leukocyte 
functions have been observed (61). Dihydroartemisinin ame-
liorated inflammatory disease (62). However, ARS-derivatives 
exhibited higher cytotoxicity in  vitro toward hematopoietic 
progenitor cells of the granulocyte-monocyte lineage (CFU-GM) 
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In conclusion, the presented case illustrates the possible 
consequences of compassionate use of non-approved drugs or 
unproven drug combinations. Drug therapy should always be in 
accordance to the guidelines of good clinical practice.
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